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Every year in Italy, the Ministry of Health (MoH) offers influenza 
vaccination free of charge to all subjects at risk and to all subjects 
aged ≥  65 year old. Until 2014-2015 immunization campaign 
against Trivalent Influenza Vaccine (TIVs) were the only vaccines 
used in Italy.
Traditional TIVs contain antigens from three viral strains: 
A(H1N1), A(H3N2), and one of the two B lineages: B(Victoria) or 
B(Yamagata). Each year, the World Health Organization (WHO) 
decides which viral strains should be included in the next sea-
sonal influenza vaccine. However, accurately predicting which 
B-lineage strain will predominate in the upcoming season has 
proved to be a challenging task, owing to the co-circulation of 
both lineages.
To address the issue of B-mismatch, a new Quadrivalent 
Influenza Vaccine (QIV) containing both B-lineage strains 
has been developed, in order to achieve broader protection 
against influenza. The new QIV was approved in Italy in 2015 
and included by the MoH in the national recommendations 
for the seasonal immunization campaign against influenza 
2015-2016.
Recently, a Health Technology Assessment (HTA) Report has 
shown that, in comparison with TIVs, the new QIV is cost-effec-
tive (Incremental Cost-Effectiveness Ratio (ICER) = € 18,883/
(QALY) Quality-Adjusted Life-Year) from the Italian National 
Health Service (NHS) perspective. The present Budget Impact 
Analysis (BIA) showed that the introduction of the QIV with 
a 9% market share in the vaccine mix for the 2015-2016 flu 
campaign would yield an annual saving of € 674,089, mainly 
owing to the broader protection offered by QIV vs TIVs with an 
estimated 49.12% B-mismatch. 
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Introduction
Every year the Italian Ministry of Health (MoH) offers 
an Influenza Immunization Program for all subjects 
at higher risk of flu complications on the basis of age 
(≥ 65 years old) or clinical and professional condition. 
Until 2014-2015 immunization campaign against influ-
enza, Trivalent Inactivated influenza Vaccines (TIVs) 
were the only vaccines used in Italy.
Traditional TIVs contain antigens from three viral 
strains: A(H1N1), A(H3N2), and one of two B lin-
eages: B(Victoria) or B(Yamagata). Each year, the 
World Health Organization (WHO) decides which viral 
strains should be included in the next seasonal influ-
enza vaccine. However, accurately predicting which B-
lineage strain will predominate in the upcoming season 
has proved to be a challenging task, resulting in fre-
quent mismatches with the vaccine strain [1], owing to 
the co-circulation of both lineages or the predominant 
circulation of the non-vaccine B-lineage. During mis-
match seasons, efficacy and effectiveness against the 
opposite B lineage are lower [2-8]. To address the issue 
of B-mismatch, a new Quadrivalent Inactivated influ-
enza Vaccine (QIV) containing both B-lineage strains 
has been developed, in order to provide broader pro-
tection against influenza. The new QIV was available 
in Italy  [9] and included by the MoH in the national 
recommendations for the seasonal immunization cam-
paign against influenza 2015-2016 [10].
Recently, a Health Technology Assessment (HTA) Re-
port has shown that, in comparison with TIVs, the new 
QIV is cost-effective (Incremental Cost-Effectiveness 
Ratio (ICER)  =  €  18,883/(QALY) Quality-Adjusted 
Life-Year) from the Italian National Health Service 
(NHS) perspective [11].
The objective of the present analysis was to estimate the 
budget impact of the new QIV after its introduction into 
the national flu immunization campaign in Italy.
Methods 
A budget impact analysis (BIA) was made from the 
NHS perspective, in order to estimate the financial im-
pact due to the introduction of the QIV into the vaccine 
mix included by the MoH in the influenza immunization 
campaign for the 2015-2016 flu season.
The BIA included the following input data:
• population eligible for influenza immunization and 
vaccine coverage (target population);
• epidemiology of influenza in Italy;
• efficacy of QIV vs TIV;
• vaccine mix and vaccine cost;
• direct influenza costs.
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The analysis considered a single-year time horizon 
and focused on the first year of QIV introduction by 
the MoH in the 2015-2016 flu immunization cam-
paign.
The results are shown as the net budget impact of the 
scenario of QIV in the flu vaccine mix (new scenario) 
versus the scenario in which only TIVs are used in the 
influenza immunization program (current scenario).
Target Population
The population targeted by the national Influenza Im-
munization Program was calculated on the basis of the 
Italian population in 2014 [12].
Every year in Italy, the MoH offers free influenza vac-
cination to all subjects at risk (for clinical/professional 
reasons) and to all subjects aged ≥ 65 year old, regard-
less of other risk factors.
The prevalence of at-risk subjects eligible for influenza 
vaccination was calculated from the data collected in 
25  EU countries (including Italy) by Ryan et al.  [13]. 
The influenza vaccine coverage data in 2014 were then 
applied to the Italian general population, in order to es-
timate the annual number of subjects undergoing influ-
enza vaccination within the national Immunization Pro-
gram [14, 15].
The target population included in the BIA is summa-
rized in Table I.
Epidemiology of influenza in Italy
The probability of contracting influenza in an unvacci-
nated population was derived from the study by Turner 
et al. and is reported in Table II [16].
The prevalence of A and B  influenza viruses circulat-
ing during a season was estimated as the average data 
(A virus = 74.12% and B virus = 25.88%) from ECDC 
Surveillance Reports from 2003 to 2012 (excluding the 
2009-2010 pandemic season) [11].
The prevalence of B-lineage strains circulating during 
a season was estimated as the average data from ECDC 
Surveillance Reports from 2003 to 2012 (B-Yamaga-
ta = 50.88% and B-Victoria = 49.12%) [11].
Efficacy of QIV vs TIV
In the present BIA, we assumed that:
• the efficacy of QIV vs TIVs in preventing influenza 
A viruses was the same; age-specific QIV and TIV 
efficacy versus influenza  A viruses is reported in 
Table III [17-19];
• the efficacy of QIV vs TIVs in preventing influ-
enza B virus was the same for the vaccine B-strain 
(matching) in TIVs but higher for the B-strain not 
Tab. I. Target population included in the BIA.
Age-
range
Population
Overall 
Vaccine 
Coverage 
(%)
Population 
at risk (%)
Population 
at risk 
vaccinated 
(%)
< 5 2,724.106 2.04 15.10 9.66
5-17 7,433.899 2.30 15.18 10.86
18-49 25,543.294 3.87 16.52 17.24
50-59 8,435.388 9.50 45.36 19.30
60-64 3,361.039 9.50 45.36 19.30
65-69 3,447.791 55.40 45.63 55.40
70-74 3,044.129 55.40 46.15 55.40
75-79 2,645.596 55.40 47.31 55.40
80-84 2,013.904 55.40 50.05 55.40
≥ 85 1,863.522 55.40 57.44 55.40
Total 60,782,688 16.33 28.66 31.02
Tab. II. Probability of contracting influenza in the population broken 
down age-range.
Age-range Probability (%)
< 5 19.21
5-17 19.21
18-49 6.55
50-59 6.55
60-64 6.55
65-69 6.17
70-74 6.17
75-79 6.17
80-84 6.17
≥ 85 6.17
Average 8.58
Tab. III. Efficacy of QIV vs TIVs in preventing influenza viruses.
Influenza A virus Influenza B virus
Age-range QIV efficacy TIV efficacy QIV efficacy TIV efficacy in match TIV in mismatch
Overall
TIV efficacy vs B virus
< 5 59% 59% 66% 66% 44% 55%
5-17 59% 59% 77% 77% 52% 64%
18-49 61% 61% 77% 77% 52% 64%
50-59 61% 61% 73% 73% 49% 61%
60-64 61% 61% 73% 73% 49% 61%
65-69 58% 58% 69% 69% 47% 58%
70-74 58% 58% 69% 69% 47% 58%
75-79 58% 58% 66% 66% 44% 55%
80-84 58% 58% 66% 66% 44% 55%
≥ 85 58% 58% 66% 66% 44% 55%
Total 59% 59% 66% 66% 44% 55%
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included in TIVs, (mismatching); these are reported 
in Table  III. In both cases, the efficacy of QIV vs 
TIVs was derived from the meta-analysis by Tricco 
et al. [20];
• the B-mismatch value considered in order to esti-
mate the overall efficacy of TIVs vs influenza B was 
49.12%.
The overall efficacy of TIVs vs influenza B virus in the 
present analysis was derived by applying the following 
formula:
TIVs Overall efficacy vs influenza B-virus = (TIV ef-
ficacy in match*B-matching) + (TIV efficacy in 
mismatch*B-mismatching)
For example, if, in subjects aged 5-17 years, the efficacy 
of TIVs vs B is 77% in the scenario of matching and 
52% in the scenario of mismatching, on considering an 
average TIV B-match of 49.12%, the overall efficacy of 
TIVs vs influenza B in that age-group is:
TIV Overall Efficacy vs influenza B virus = (77%*100%-
49.12%)+(52%*49.12%) = 64%
Vaccine mix and vaccine cost
The BIA was conducted by comparing two scenarios:
Current scenario: this scenario included only TIVs 
in the vaccination strategy, and the vaccine mix was 
based on the TIV doses included in the allotments re-
quested by the 20 Italian Regions for the 2014-2015 
flu season (when QIV was not yet available on the 
market); specifically, the vaccine mix in the analysis 
included:
• inactivated trivalent split influenza virus vaccine 
(Split);
• intradermal influenza vaccine (Intradermal);
• adjuvanted influenza vaccine (Adjuvanted).
New scenario: this scenario included the QIV as an 
alternative to TIVs and the vaccine mix was based 
on QIV and TIV doses included in the allotments re-
quested by the 20 Italian Regions for the 2015-2016 
flu season; specifically, the vaccine mix in the analy-
sis included: 
• inactivated trivalent split influenza virus vaccine 
(Split);
• intradermal influenza vaccine (Intradermal);
• adjuvanted influenza vaccine (Adjuvanted);
• inactivated tetravalent split influenza virus vaccine 
(QIV).
It was assumed that in both scenarios the B-strain in-
cluded in TIVs was Yamagata, in accordance with TIV 
antigen composition in the 2014-2015 and 2015-2016 
flu seasons.
Vaccine prices in the analysis were based on the average 
regional tender price in the 2015-2016 flu season. 
The vaccine mix and vaccine prices in both scenarios are 
summarized in Table IV.
Direct influenza cost 
The analysis estimated one-year health resource con-
sumption related to influenza, with or without the intro-
duction of QIV into the National Influenza Immuniza-
tion program.
Table V reports the direct costs included in the analy-
sis and the probabilities that patients with influenza will 
generate these costs.
The analysis also took into account the frequency and 
the cost of influenza patients with complications:
• the frequency of complications in patients with influ-
enza, regardless of age, was 29.46%; this was esti-
mated from the data reported by Sessa et al. [21];
• the frequency of complications requiring hospitaliza-
tion was 11.56% for subjects at risk and 7.15% for 
subjects not at risk [26];
• in the analysis, it was assumed that 90.77% of these 
complications requiring hospitalization were respira-
tory, and that 9.23% were other complications unre-
lated to the respiratory tract.
Tab. IV. Unit prices and market shares of the vaccines in the BIA.
Vaccine Current scenario New scenario
Market share (MS) Unit price Market share (MS) Unit price
Split 49% 2.55 € 52% 2.55 €
Intradermal 26% 5.36 € 25% 5.36 €
Adjuvanted 25% 5.33 € 14% 5.33 €
QIV 0 0 9% 6.00 €
Total 100% 100%
Tab. V. Cost of influenza: direct costs included in the BIA and probabilities that patients with influenza will generate these costs.
Health resource
Probability of generating the cost 
for patients with influenza (%)
Cost Source
GP consultation 60% 20.66 € [21]
Antibiotic therapy 47.3%
3.53 € (< 18 years)/ 
3.06 € (≥ 18years)
Final cost on multiplying the initial cost by the 
likelihood of receiving antibiotics [22, 23]
Antiviral therapy 0.17%
17.3 € (< 5years) /  
38.5 € (≥ 5years)
[24, 25]
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Table VI reports the costs of complications in inpatient 
(hospitalization) and outpatient settings, based on DRG 
tariffs.
Results
The objective of this analysis was to estimate the budget 
impact of the new QIV after its introduction into the Na-
tional Immunization campaign in Italy.
In the base-case scenario, we assumed that, in the 2015-
2016 flu season:
• the TIVs used contained the Yamagata B-strain;
• the prevalence of A and B viruses circulating during 
the 2015-2016 flu season was 74.12% and 25.88%, 
respectively, and that of the Yamagata and Victoria B-
strains circulating during the same year was 50.88% 
and 49.12%, respectively;
• the QIV was used in 9% of the population eligible 
for the National Influenza Immunization campaign 
in Italy;
• the price of a single dose of QIV was 6.00 €.
The results of the base-case scenario are shown in Ta-
bles VII and VIII. The base-case scenario simulated 
the impact of QIV introduction on the basis of the real 
volumes of influenza vaccines requested by the Italian 
Regions for the 2015-2016 flu season, in comparison 
with the vaccine mix without QIV and based on the 
TIV volume requested by the Italian Regions for the 
2014-2015 flu season (when QIV was not yet on the 
market).
Comparison of the two scenarios (new versus current) 
revealed that, according to the estimates in the present 
analysis (49.12% B-mismatch), the introduction of QIV 
would prevent 1,601 influenza events (including 1,031 
with complications), as a consequence of the broader 
protection of QIV against B-strain virus.
This broader protection of QIV vs TIVs in the new sce-
nario resulted in a saving of € 419,389 in the annual 
influenza treatment costs borne by the NHS. Although 
the cost of introducing QIV at 9% (858,538 units) was 
€ 5,151.230 (due to the higher purchase cost of QIVs vs 
TIVs), it was fully offset by the 3% increase in the MS 
of the split vaccines and the 12% decrease in the MS of 
the intradermal vaccine and adjuvanted vaccine, which 
yielded a saving of € 5,405.930. Thus, the net result of 
introducing QIV on the cost of vaccination was a sav-
ing of € 254,700.
The estimated net budget impact of the introduction of 
QIV into the National Influenza Immunization program 
in the flu season 2015-2016 was a saving of € 674,089 vs 
the scenario with no QIV.
The BIA considered two alternative scenarios in addi-
tion to that of the base-case:
no B-mismatch:
• prevalence of A and B  influenza virus circulat-
ing during a season: A virus = 74.12% and B virus 
= 25.88%;
• prevalence of B-lineage strains circulating: B-Ya-
magata = 100% and B-Victoria = 0%;
• the QIV was used in 9% of the population eligible 
for the National Influenza Immunization campaign 
in Italy;
• the price of a single dose of QIV was € 6.00;
• TIVs contained the Yamagata B-strain.
Tab. VII. Impact of the introduction of a QIV in Italy on influenza 
cases: base-case results.
Current 
scenario
New or 
alternative 
scenario
∆ (avoided 
cases with 
new scenario)
Subjects covered 
by vaccination
9,539.315 9,539.315
With TIVs 9,539.315 8,680.777
With QIV 0 858,538
Influenza 
events without 
complications 
in immunized 
subjects
255,703 254,102 -1,601
Influenza 
events with 
complications 
in immunized 
subjects
166,596 165,565 -1,031
Bronchitis in 
immunized 
subjects
69,924 69,491 -433
Pneumonia 
in immunized 
subjects
6,351 6,312 -39
Upper 
respiratory tract 
infections (URTI) 
in immunized 
subjects
74,944 74,481 -464
Other 
complications 
not related to 
respiratory tract 
in immunized 
subjects
15,377 15,282 -95
Hospitalization 
in immunized 
subjects
16,073 15,973 -100
Tab. VI. Costs of influenza complications: inpatient and outpatient settings.
Respiratory complications Inpatient cost < 18 years Inpatient cost ≥ 18 years Outpatient
Bronchitis 1,538 € 1,832 € 90 €
Pneumonia 1,948 € 2,291 € 90 €
Upper Respiratory Tract Infections (URTI) 5,768 € €4,422 €90
Other complications not related to respiratory tract 2,777 € 2,900 € 83 €
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full B-mismatch:
• prevalence of A and B  influenza virus circulat-
ing during a season: A virus = 74.12% and B virus 
= 25.88%;
• prevalence of B-lineage strains circulating: B-Ya-
magata = 0% and B-Victoria = 100%;
• the QIV was used in 9% of the population eligible 
for the National Influenza Immunization campaign 
in Italy;
• the price of a single dose of QIV was € 6.00;
• TIVs contained the Yamagata B-strain.
Figures 1 and 2 summarize the results from these two 
additional scenarios versus the base-case.
In the No B-mismatch scenario, there was no impact 
of QIV introduction in preventing influenza cases ver-
sus TIVs, owing to the complete match between the B-
strain circulating and the B-strain contained in the TIVs. 
Nevertheless, the net budget impact in this scenario was 
favourable, because the incremental cost due to QIV in-
troduction was fully offset by increased use of split vac-
cine (Market Share (MS) +3%) and the decreased use of 
intradermal vaccine and adjuvanted vaccine (MS -12%), 
produced a net saving of € 254,700 in a year.
In the Full  B-mismatch scenario, the influenza cases 
avoided through the introduction of QIV was 3,120. In 
this scenario, the broader protection offered by QIV vs 
TIVs was maximized by the 100% mismatch between 
the B-strain circulating and the B-strain contained in the 
TIVs. The net budget impact in this scenario was highly in 
favour of the introduction of QIV, with € 1,087.382 saved 
in one year. The majority of this saving came from the 
reduction in influenza treatment costs produced by QIV 
versus TIVs, owing to the full B-mismatch (-€ 832,692).
Discussion
The WHO and European Health Authorities encouraged 
the development of QIV in order to achieve broader 
protection against influenza by reducing the impact of 
Tab. VIII. Impact of the introduction of a QIV in Italy on direct influenza costs: base-case results.
Current scenario (€) New Scenario (€) ∆ (€)
Vaccination cost 37,924.500 37,669.800 -254,700
TIVs 37,924.500 32,518.570
QIV 0 5,151.230
Cost of influenza 3,559.199 3,536.906 -22,293
GP consultation 3,169.698 3,149.846 -19,852
Antibiotic therapy 372,881 370,543 -2,337
Antiviral therapy 16,620 16,516 -104
Cost of influenza with complications 63,844.008 63,446.912 -397,096
Inpatient cost 50,394.190 50,080.269 -313,920
Outpatient cost 13,449.818 13,366.643 -83,176
Total 105,327.707 104,653.618 -674,089
Fig. 1. Number of avoided cases of influenza due to QIV introduction  in the 3 scenarios included in the BIA.
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B-Mismatch. Until 2014-2015 immunization campaign 
against influenza, only TIVs were available for the Na-
tional Influenza Immunization campaign in Italy. Tra-
ditional TIVs contain antigens from three viral strains: 
A  (H1N1), A  (H3N2), and one of two co-circulating 
B lineages: B(Victoria) or B(Yamagata). Each year, the 
WHO decides which viral strains should be included in 
the next seasonal influenza vaccine.
However, accurately predicting which B-lineage strain will 
predominate in the upcoming season has proved to be a 
challenging task, resulting in frequent mismatches with the 
vaccine strain. During mismatch seasons, efficacy and ef-
fectiveness against the opposite B lineage are lower because 
of the lack of cross-protection of the B-strain contained in 
the TIVs vs the circulating B-strain, when they differ.
In 2015, the first QIV was approved by the Italian Drug 
Agency (AIFA), and was included in the National In-
fluenza Immunization campaign by the MoH for the 
2015/2016 flu season.
An HTA Report showed that this new QIV was more 
cost-effective than TIVs (ICER = € 18,883/QALY) from 
the Italian NHS perspective.
In the present analysis, we estimated the BIA after the 
introduction of QIV as an alternative to TIVs. The BIA 
showed that, with a 9% MS in the vaccine mix for the 
2015-2016 flu campaign, the introduction of the QIV 
yielded an annual saving of €  674,089, mainly due to 
the broader protection offered by QIV vs TIVs with an 
estimated 49.12% B-mismatch.
QIV is an effective and safe alternative to TIVs, offering 
broader protection when B-mismatch occurs in the flu sea-
son. From the NHS perspective, QIV is cost-effective in 
Italy; our budget impact analysis estimated that the intro-
duction of QIV into the influenza immunization campaign 
in 2015/2016 would produce a net annual saving ranging 
from € 254,700 (0% B-mismatch, Incremental cost of QIV 
fully offset by the saving due to the increased MS of split 
vaccines and the decreased MS of intradermal and adju-
vanted vaccines) to € 1,087,392 (100% B-mismatch).
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